<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2020000100006</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2020000100006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Terapia combinada con bevacizumab y alteplasa para el tratamiento de hemorragias submaculares]]></article-title>
<article-title xml:lang="en"><![CDATA[Combined therapy with bevacizumab and alteplasa for the treatment of submacular hemorrhages]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Belló-Crespo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montero-Hernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Pérez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lorente-Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soler-Company]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Arnau de Vilanova-Llíria Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Arnau de Vilanova-Llíria Servicio de Oftalmología ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>30</volume>
<numero>1</numero>
<fpage>15</fpage>
<lpage>19</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2020000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2020000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2020000100006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: El uso combinado de bevacizumab y alteplasa intrarretiniano supone una alternativa de tratamiento de las hemorragias maculares que adquiere cada vez más relevancia. Además, su utilización en una única jeringa evita una inyección intrarretiniana reduciendo los posibles riesgos que conllevan.  Objetivo: Confirmar la efectividad y seguridad de la combinación de bevacizumab y alteplasa in vivo para el tratamiento de hemorragias submaculares en pacientes con degeneración macular asociada a la edad y determinar si supone una alternativa de tratamiento válida.  Metodología: Estudio retrospectivo observacional de pacientes tratados con bevacizumab y alteplasa para hemorragias submaculares desde febrero de 2017 a febrero de 2018. Se revisó la situación clínica pre-intervención y a los 3 meses. Las variables revisadas para determinar la efectividad del tratamiento fueron el tamaño de la superficie de la hemorragia, el grosor retiniano y la agudeza visual. La seguridad se evaluó con la aparición de reacciones adversas.  Resultados: Fueron incluidos cinco pacientes, cuatro con un ojo afectado y uno con ambos, 60% hombres, con una mediana de edad de 78 años (68-89). Objetivamente se redujo el porcentaje de ocupación de la hemorragia de una media del 70% al 6% tras la intervención. El grosor retiniano disminuyó de 1.531 micras (1.891-1.195) a 516,8 micras (324-667). La agudeza visual mejoró en dos pacientes manteniéndose en el resto. Todos los pacientes refirieron subjetivamente mejoría tras la intervención. El tratamiento fue seguro por la ausencia de aparición de reacciones adversas.  Conclusiones: El tratamiento estudiado ha demostrado ser efectivo y seguro clínicamente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Introduction: The combined use of bevacizumab and intraretinal alteplase is an alternative treatment for macular hemorrhage that is becoming more and more relevant. In addition, its use in a single syringe prevents an intraretinal injection reducing the possible risks involved.  Objective: To confirm the effectiveness and safety of the combination of bevacizumab and alteplase in vivo for submacular hemorrhage in patients with macular degeneration associated with age and to determine whether it is a valid treatment alternative.  Material and methods: Observational retrospective study of patients treated with bevacizumab and alteplase for submacular hemorrhages from February 2017 to February 2018. The clinical situation was reviewed pre-intervention and at 3 months later. The variables reviewed to determine the effectiveness of the treatment were the size of the hemorrhage surface, the retinal thickness and the visual acuity. Safety was determined with the appearance of adverse reactions.  Results: Six eyes of five patients were included, 60% men, with a median age of 78 years (68-89). Objectively the percentage of occupation of the hemorrhage was reduced from an average of 70% to 6% after the intervention. The retinal thickness decreased from 1,531 microns (1,891-1,195) to 516.8 microns (324-667). Visual acuity improved in two patients and remained in the rest. All patients reported subjectively improvement after the intervention. The treatment was safe due to the absence of adverse reactions.  Conclusions: The reviewed treatment has shown to be clinically effective and safe.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hemorragia macular]]></kwd>
<kwd lng="es"><![CDATA[degeneración macular asociada a la edad]]></kwd>
<kwd lng="es"><![CDATA[bevacizumab]]></kwd>
<kwd lng="es"><![CDATA[alteplasa]]></kwd>
<kwd lng="en"><![CDATA[Macular hemorrhage]]></kwd>
<kwd lng="en"><![CDATA[age related macular degeneration]]></kwd>
<kwd lng="en"><![CDATA[bevacizumab]]></kwd>
<kwd lng="en"><![CDATA[alteplase]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stanescu-Segall]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Balta]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature]]></article-title>
<source><![CDATA[Surv Ophthalmol]]></source>
<year>2016</year>
<volume>61</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-32</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bloome]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Massive spontaneous subretinal hemorrhage]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>1978</year>
<volume>86</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>630-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Humayun]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Flynn]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Sternberg]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Blumenkranz]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of submacular hemorrhage associated with retinal arterial macroaneurysms]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>1998</year>
<volume>126</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>358-61</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shiraga]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yokoe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Takasu]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Okanouchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ohtsuki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgical treatment of submacular hemorrhage associated with idiopathic polypoidal choroidal vasculopathy]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>1999</year>
<volume>128</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>147-54</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yannuzzi]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Sorenson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Spaide]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Lipson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Idiopathic polypoidal choroidal vasculopathy (IPCV)]]></article-title>
<source><![CDATA[Retina]]></source>
<year>2012</year>
<volume>32</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luna]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Reviglio]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bilateral macular hemorrhage after laser in situ keratomileusis]]></article-title>
<source><![CDATA[Graefes Arch Clin Exp Ophthalmol]]></source>
<year>1999</year>
<volume>237</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>611-3</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hattenbach]]></surname>
<given-names><![CDATA[LO]]></given-names>
</name>
<name>
<surname><![CDATA[Klais]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Koch]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Gümbel]]></surname>
<given-names><![CDATA[HO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2001</year>
<volume>108</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1485-92</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliver]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Packo]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[MacCumber]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Awh]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in Age-Related macular degeneration]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2004</year>
<volume>111</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1201-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jager]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Aiello]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risks of intravitreous injection: a comprehensive review]]></article-title>
<source><![CDATA[Retina]]></source>
<year>2004</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>676-98</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Ulla]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Basauri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Sanz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of intravitreal injections]]></article-title>
<source><![CDATA[Arch Soc Esp Oftalmol]]></source>
<year>2009</year>
<volume>84</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>377-88</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klettner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Puls]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Treumer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Roider]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hillenkamp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility of Recombinant Tissue Plasminogen Activator and Bevacizumab Co-Applied for Neovascular Age-Related Macular Degeneration With Submacular Hemorrhage]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>2012</year>
<volume>130</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>875-81</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treumer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Klatt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Roider]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hillenkamp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2010</year>
<volume>94</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-53</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treumer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wienand]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Purtskhvanidze]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Roider]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hillenkamp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF]]></article-title>
<source><![CDATA[Graefes Arch Clin Exp Ophthalmol]]></source>
<year>2017</year>
<volume>255</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1115-23</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montes-Vera]]></surname>
<given-names><![CDATA[M del R]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido-Acosta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Anguiano-Robledo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Navarrete]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Cruz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos farmacocinéticos de bevacizumab]]></article-title>
<source><![CDATA[Rev Hosp Jua Mex]]></source>
<year>2013</year>
<volume>80</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klettner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grotelüschen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Treumer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Roider]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hillenkamp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2015</year>
<volume>99</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>864-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Folk]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Blodi]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Klugman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors prognostic of visual outcome in patients with subretinal hemorrhage]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>1990</year>
<volume>109</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berrocal]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Flynn]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variations in the clinical course of submacular hemorrhage]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>1996</year>
<volume>122</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>486-93</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
